Omalizumab as an adjuvant therapy for treating severe atopic dermatitis in children. A series of cases

Simple item page
dc.contributor.authorMaría Alejandra García
dc.contributor.authorAlejandro Durán Crane
dc.contributor.authorEdgardo Chapman
dc.contributor.authorElizabeth García
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T15:06:20Z
dc.date.available2026-03-22T15:06:20Z
dc.date.issued2019
dc.descriptionCitaciones: 7
dc.description.abstractOmalizumab appears promising for treating severe atopic dermatitis in pediatric patients. That results shows that omalizubam improves the quality of life, also decreases the severity of the disease and the need for systemic steroid and immunosuppressive therapy, which decreases the side effects that are caused by these medications.
dc.identifier.doi10.29262/ram.v66i3.401
dc.identifier.urihttps://doi.org/10.29262/ram.v66i3.401
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/50408
dc.language.isoen
dc.publisherColegio Mexicano de Inmunología Clínica y Alergia, A.C.
dc.relation.ispartofRevista Alergia México
dc.sourceFundación Universitaria de Ciencias de la Salud
dc.subjectMedicine
dc.subjectAtopic dermatitis
dc.subjectOmalizumab
dc.subjectSCORAD
dc.subjectQuality of life (healthcare)
dc.subjectDermatology Life Quality Index
dc.subjectDermatology
dc.subjectDisease
dc.subjectAdjuvant therapy
dc.subjectAllergy
dc.titleOmalizumab as an adjuvant therapy for treating severe atopic dermatitis in children. A series of cases
dc.typearticle

Files

Collections

Artículo Científico Publicado